TMA will be participating in Rare Disease Week on Capitol Hill February 24th- February 28th hosted by Rare Disease Legislative Advocates (RDLA). During Rare Disease Week on Capitol Hill 2019, RDLA plans to bring together over 500 patient advocates in Washington, DC for a week of events dedicated to empowering patients, families, friends, and healthcare professionals to become…
Continue Reading
Corbus Pharmaceuticals is now recruiting dermatomysitis patients for an exciting phase 3 clinical trial for lenabasum. The trial, known as DETERMINE, is designed to evaluate the efficacy and safety of lenabasum for the treatment of dermatomyositis.
Continue Reading
As part of a new Lunch n’ Learn program at TMA, representatives from BriovaRx visited TMA offices yesterday to teach staff and one of our members about home infusion services and immunoglobulin (IgG) therapy for myositis diseases.
Continue Reading
TMA is thrilled to be chosen as Charity of the Month for December by two radio stations in the Washington, DC area.
Continue Reading
The Myositis Association (TMA), the leading international patient organization dedicated to improving the lives of people affected by myositis, is pleased to announce the appointment of the following individuals to its distinguished Medical Advisory Board:
Continue Reading